On June 30, 2025, WuXi XDC's new manufacturing facility at Tuas Biomedical Park in Singapore successfully reached mechanical completion, marking a major milestone in the company’s modular plant project in partnership with Pharmadule Morimatsu AB. Spanning approximately 25,000 square meters, the site will now enter a comprehensive phase of equipment installation, facility commissioning, and validation. The facility is on track to become fully operational by the end of 2025, with GMP (Good Manufacturing Practice) production expected to begin in 2026. Once fully operational, the facility will offer end-to-end production capabilities from preclinical development to commercial manufacturing.

With its strong engineering, design expertise, and exceptional supply chain coordination, Pharmadule Morimatsu AB has played a key role in helping WuXi XDC establish a cutting-edge bioconjugate drug manufacturing site. The main facility is built from more than 200 modules supplied by Pharmadule Morimatsu AB. These highly integrated, scalable modular solutions have significantly improved construction efficiency and quality, while also accelerating the overall project timeline. Construction began at Morimatsu's facility in China in June 2024, with phased module shipments starting in November 2024. By June 2025, the project reached seamless mechanical completion on-site in Singapore—completing the entire process in just about one year. This achievement showcases a model of efficient, high-quality, and high-standard delivery, offering customers dependable and predictable project execution.

Group Photo of the Pharmadule Morimatsu AB Project Team

This collaboration reflects both parties' deep understanding of and agile response to the growing global demand for bioconjugate drugs, and also highlights the project team’s outstanding execution efficiency. Featuring Pharmadule Morimatsu AB’s state-of-the-art modular plant design, WuXi XDC’s Singapore facility has incorporated world-class production lines for antibody intermediates, conjugated drug substances, and conjugated drug products. The facility also includes process science and technology labs, quality control areas, intelligent warehousing, and comprehensive utility support systems. The facility is outfitted with industry-leading isolator filling lines, fully automated material handling systems, and digital production management platforms. It is able to support a full range of needs from small-scale clinical supply to large-scale commercial manufacturing.

Throughout construction, Pharmadule Morimatsu AB prioritized environmental protection and sustainability, creating a green, intelligent, and highly efficient modern manufacturing site for WuXi XDC. The Singapore facility is built to the highest global quality standards, fully compliant with GMP regulations. It ensures end-to-end quality and regulatory control from antibody intermediates to drug substance manufacturing and final drug product filling, supporting seamless global product release. In line with ESG principles, the facility also incorporates certified eco-friendly materials and is equipped with robust recycling and waste management systems, promoting sustainable practices across the entire biopharmaceutical value chain.

Pharmadule Morimatsu AB and WuXi XDC will continue to strengthen their collaboration, working closely on the ongoing development and future operations of the Singapore facility. Together, they aim to drive the diversified growth of conjugated drug technologies and accelerate the efficient translation of biopharmaceutical innovations into accessible therapies for patients around the world.